Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Two-Part, Phase 1B Clinical Study of CMP-001 in Combination With Atezolizumab With and Without Radiation Therapy in Subjects With Advanced Non Small Cell Lung Cancer (NSCLC)

Next Previous
X
Search
Trial Profile

A Multicenter, Two-Part, Phase 1B Clinical Study of CMP-001 in Combination With Atezolizumab With and Without Radiation Therapy in Subjects With Advanced Non Small Cell Lung Cancer (NSCLC)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Vidutolimod (Primary) ; Vidutolimod (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Regeneron Pharmaceuticals

    • Most Recent Events

    • 13 Apr 2022 Results presented at the 113th Annual Meeting of the American Association for Cancer Research
    • 08 Apr 2022 Results published in the Checkmate Pharmaceuticals Media Release.
    • 08 Apr 2022 According to a Checkmate Pharmaceuticals media release, biomarker signature data from the study will be presented at the 2022 American Association for Cancer Research (AACR) Annual Meeting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top